

Asgerdur Sverrisdottir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11360617/publications.pdf>

Version: 2024-02-01

7
papers

160
citations

1937685

4
h-index

1872680

6
g-index

7
all docs

7
docs citations

7
times ranked

263
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	9.4	79
2	Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. <i>European Urology</i> , 2018, 73, 870-876.	1.9	44
3	Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 755-763.	2.5	26
4	BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz100.	2.9	7
5	Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5559-5559.	1.6	2
6	In situ breast cancer incidence patterns in Iceland and differences in ductal carcinoma in situ treatment compared to Sweden. <i>Scientific Reports</i> , 2020, 10, 17623.	3.3	1
7	CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5569-5569.	1.6	1